Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma

Cancer

Volumn 83, Issue 7, 1998, Pages 1355-1361

  Kelley, Mark C ^a,b   Jones, Ralph C ^a,c   Gupta, Rishab K ^a   Yee, Reynold ^a   Stern, Stacey ^a   Wanek, Leslie ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Melanoma; Occult metastasis; Prognostic factor; TA 90 immune complexes; Tumor marker; Tumor associated antigen

Indexed keywords

TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER SURVIVAL; EXCISION; FEMALE; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OCCULT CANCER; PRIORITY JOURNAL;

ADULT; AGED; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032189660     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981001)83:7<1355::AID-CNCR12>3.0.CO;2-3     Document Type: Article

References (20)

1. Norton JA, Fraker DL. Tumor markers. In: Sabiston DS. Sabiston textbook of surgery. New York: W. B. Saunders, 1996.
2. Pandha HS, Waxman J, Sikora K. Tumor markers. Br J Hosp Med 1994;51:297-303.
3. Schadendorf D, Zuberbier T, Diehl S, Schadendorf C, Czarnetzki BM. Serum manganese Superoxide dismutase is a new tumor marker for malignant melanoma. Melanoma Res 1995;5:351-3.
4. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994;73:629-36.
5. Miliotes G, Lyman GH, Cruse CW, Puelo C, Albertini J, Rappaport D, et al. Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 1996;3:558-63.
6. Hansson J. Systemic therapy of malignant melanoma. Med Oncol 1997;14:73-81.
7. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-49.
8. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST-1684. J Clin Oncol 1996; 14:7-17.
9. Rote NS, Gupta RK, Morton DL. Tumor-associated antigens detected by autologous sera in the urine of patients with solid neoplasms. J Surg Res 1980;29:18-22.
10. Euhus DM, Gupta RK, Morton DL. Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients, Int J Cancer 1990;45:1065-70.
11. Gupta RK, Morton DL. Monoclonal antibody based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in the sera of cancer patients. J Clin Lab Anal 1992;6:329-36.
12. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989;29:247-54.
13. Jones RC, Kelley MC, Gupta RK, Nizze JA, Yee R, Leopoldo Z, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-45.
14. Gupta RK. Circulating immune complexes in malignant melanoma. Dis Markers 1988;6:81-96.
15. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, et al. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA and New South Wales, Australia. Ann Surg 1982;196:677-84.
16. Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71:3737-43.
17. Morton DL, Wen D-R, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg 1992; 127:392-9.
18. Balch CM, Buzaid AC. Finally, a successful adjuvant therapy for high-risk melanoma [editorial]. J Clin Oncol 1996;14:1-3.
19. Cochran AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. Am J Surg Pathol 1988;12:612-8.
20. Day CL, Mihm MC, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51-3.99 mm). Ann Surg 1982;195:35-43.